DIAGNOS Healthcare (India) Pvt. Ltd. Announces the Signing of a Letter of Intent with Aditya Jyot - a Leading Indian Ophthalm...
13 Janvier 2014 - 6:00PM
Marketwired
DIAGNOS Healthcare (India) Pvt. Ltd. Announces the Signing of a
Letter of Intent with Aditya Jyot - a Leading Indian Ophthalmic
Research and Treatment Eye Hospital
MUMBAI, INDIA--(Marketwired - Jan 13, 2014) - Diagnos Healthcare
(India) Pvt. Ltd. ("DIAGNOS India" or "the Corporation"), a
subsidiary of DIAGNOS Inc. (TSX-VENTURE:ADK) a leader in healthcare
technical services including, screening, software and algorithm
development, data analysis, and image processing, announces the
signing of a Letter of Intent to conclude a Channel Agreement with
Aditya Jyot Eye Hospital, a leading Ophthalmic Research and
Treatment Organization in India.
Under the terms of the LOI, DIAGNOS India will provide its CARA
screening services to its client initially in Maharashtra followed
by national expansion to areas where Aditya Jyot is active. DIAGNOS
India plans to deploy and operate both Mobile and Managed screening
services on behalf of the client and screen up to 30,000 patients
annually. A formal channel partnership is to be concluded within 90
days.
"We are very pleased to have been selected by Aditya Jyot as a
service provider for their screening needs. We very much look
forward to serving them and their patients and to working alongside
their world-renowned retinal surgeons. The current plan calls for
the deployment of a co-branded service including vehicles, cameras,
and screening personnel equipped with our internationally
recognized CARA platform. We are pleased to have Aditya Jyot's
interest and support. We look forward to serving a broader Indian
population and helping our client achieve greater practice
efficiency through our screening service utilizing our telemedicine
platform," said Peter Nowacki, Diagnos Vice-President and Director
of Diagnos India.
About Aditya Jyot Eye
Hospital
Voted by outlookindia.com as the #1 eye care institution in the
State of Maharashtra and #5 overall in India, Aditya Jyot Eye
Hospital strives to provide world class eye care service under one
roof by innovative service through research, patient-focused care
with 100% patient satisfaction, zero percent error, patient
education, and innovative services. For more information visit
www.adityajyoteyehospital.org.
About CARA
CARA is a tele-ophthalmology platform that integrates with
existing ophthalmic imaging equipment (hardware and software) and
processes retinal images at the point of care (POC).The system
comprises: image upload, image enhancement automated pre-screening,
grading by a specialist, and referral to a specialist. CARA's image
enhancement algorithms make standard retinal images sharper,
clearer, and easier to read. CARA is accessible securely over the
internet, and is compatible with all recognized image formats and
brands of fundus cameras, and is EMR compatible. CARA is a
cost-effective tool for screening large numbers of patients in
real-time and has been approved by regulatory authorities including
Health Canada, US Food and Drug Administration, and the European
Union.
About DIAGNOS
HEALTHCARE (INDIA) PRIVATE LIMITED
DIAGNOS HEALTHCARE (INDIA) PRIVATE LIMITED was incorporated in
Mumbai, Maharashtra, India, under the Indian Companies Act to
support and coordinate deployment and usage of CARA in India. It is
owned 99% by DIAGNOS Inc. Currently it has one office in Mumbai
which serves as a coordination centre for Mumbai and New Delhi
mobile screening units.
About
DIAGNOS
Founded in 1998, DIAGNOS is a publicly traded Canadian
corporation with a mission to commercialize technologies combining
contextual imaging and traditional data mining thereby improving
decision making processes. DIAGNOS offers products, services, and
solutions to clients in a variety of fields including healthcare
and natural resources.
Forward-looking
information
This document contains forward-looking information. There can be
no assurance that forward-looking information will prove to be
accurate, as actual results and future events could differ
materially from those anticipated in these statements.
Neither the TSX Venture Exchange nor its Regulation Service
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
For further information on DIAGNOS, please visit our website at
www.diagnos.com or the SEDAR website at www.sedar.com.
Andre LarentePresident, DIAGNOS Inc.(450) 678-8882 ext 224Louis
MorinBid Capital Markets(514) 845-1101
Diagnos (TSXV:ADK)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Diagnos (TSXV:ADK)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024